Effects of the Long-Acting Human Glucagon-Like Peptide-1 Analog Liraglutide on β-Cell Function in Normal Living Conditions
Open Access
- 1 August 2007
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 30 (8) , 2032-2033
- https://doi.org/10.2337/dc07-0310
Abstract
This study includes data used for a different analysis in a previous publication (3), where the experimental protocol, approved by the local ethics committee and performed in accordance with the Helsinki Declaration, was described in detail.Keywords
This publication has 6 references indexed in Scilit:
- Mathematical Modeling Shows Exenatide Improved β-Cell Function in Patients with Type 2 Diabetes Treated with Metformin or Metformin and a SulfonylureaHormone and Metabolic Research, 2006
- Glucagon-like peptide 1 and its derivatives in the treatment of diabetesRegulatory Peptides, 2005
- One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 DiabetesDiabetes, 2004
- The GLP-1 Derivative NN2211 Restores β-Cell Sensitivity to Glucose in Type 2 Diabetic Patients After a Single DoseDiabetes, 2003
- Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjectsAmerican Journal of Physiology-Endocrinology and Metabolism, 2002
- Assessing Insulin Secretion by Modeling in Multiple-Meal TestsDiabetes, 2002